Kornimate/medical-research-clean huggingface dataset:
comparative study between ube and petd for the treatment of lumbar spinal canal stenosis

Conditions: Lumbar Disc Herniation

Summary: objective both unilateral biportal endoscopy technique(ube) and percutaneous endoscopic transforaminal discectomy(petd) are minimally invasive and effective surgical procedures for lumbar spinal stenosis.the object of this retrospective study was to compare the clinical and radiological outcomes between ube and petd. methods in the period from july 2020 to december 2020, using ube or petd to treat lumbar canal stenosis.patients were classified into two groups based on the surgery they had undergone. preoperative and postoperative mr image was used to evaluate the removal rate of lumbar disc herniated material by two surgical methods. the two surgical methods are also compared and evaluated in terms of operation time, incision size, hospitalization time, etc.

it was performed as a retrospective analysis of prospectively collected data on patients received spinal endoscopic decompression between july 2020 to december 2020 was conducted. all patients underwent lumbar mri examination with the result of l5-s1 disc herniation，accompanied by claudication or lower extremity radiation pain and other nerve compression symptoms. the symptoms have not improved with conservative treatments including physical therapy, medication, and epidural injection procedures for a minimum of 12 weeks. patients who hadprevious spine surgery, infection, trauma, tumors or spondylolisthesis were excluded. the surgery was performed by the same experienced spinal surgeon and the surgical patient were closely followed for 3 months after surgery. the investigators performed two kinds of endoscopic lumbar discectomy：unilateral biportal endoscopy technique(ube) and percutaneous endoscopic transforaminal discectomy(petd).

Eligibility criteria:
inclusion criteria: - single-segment lumbar disc herniation/lumbar spinal stenosis exclusion criteria: * multi-segment lumbar disc herniation / lumbar spinal stenosis、have received surgery、hypertension、diabetes inclusion criteria: inclusion criteria: single-segment lumbar disc herniation symptoms of nerve compression exclusion criteria: foraminal and extraforaminal disc herniation multilevel disc herniation, spinal stenosis spondylolisthesis scoliosis prior lumbar surgery spinal infection spinal tumor a history of hip or knee arthritis
lysosomal movement and anabolic resistance

Conditions: Sarcopenia

Summary: age-associated loss of muscle mass, termed sarcopenia, is strongly associated with functional impairment and physical disability in the elderly. maintenance or growth of muscle mass is mainly driven by increased muscle protein synthesis (i.e. the generation of new muscle protein) in response to exercise and feeding. however, several investigations have shown that elderly individuals have a blunted protein synthetic response following protein intake. this inability of the elderly to properly respond to growth stimuli has been termed anabolic resistance and plays a significant role in the development of sarcopenia. however, the precise mechanisms underpinning anabolic resistance are unknown. it is well established that muscle protein synthesis at the molecular level is regulated by a cellular protein complex called mtorc1. when exposed to a growth stimulus, mtorc1 has been shown to associate with lysosomes, i.e. the intracellular organelles responsible for the breakdown of cellular proteins, and subsequently moving towards the cell periphery. this movement of lysosome-associated mtorc1 within the cell is believed to be vital for the activation of protein synthesis, as inhibition of lysosomal movement blunts mtorc1 activation in response to amino acids. thus, dysregulation of lysosomal movement in ageing muscle may represent an underlying mechanism in the development of anabolic resistance. however, this area of research is unexplored in the context of human skeletal muscle. the investigators hypothesize that dysregulation of lysosomal movement plays a central role in the development of age-associated skeletal muscle anabolic resistance.


Eligibility criteria:
inclusion criteria: be a non-smoking male within the specified age range for each group (young; 18-35 yrs, old; 65-75 yrs) have a bmi (body mass index, body weight/height in m2) between 18 and 25 kg/m2, which is considered a normal body mass index. be in good general health: no cardiovascular diseases or metabolic diseases. exclusion criteria: health problems such as: heart disease , metabolic disease such as phenylketonuria, rheumatoid arthritis, uncontrolled hypertension, poor lung function, or any health condition that might put the participant at risk when participating in this study. generalized neuromuscular disease (such as parkinson's disease or motorneuron disease). involvement in regular structured resistance exercise training at the time of the study. consumption of any analgesic drugs, anti-inflammatory drugs, or medication that is known to affect protein metabolism (beta-blockers, corticosteroids, nsaids). participants who have undergone muscle biopsy testing or isotope infusion procedures within the last 5 years. allergic to lidocaine
improving self management skills of older adults with diabetes

Conditions: Type 2 Diabetes; Diabetes

Summary: the study will help determine if the better choices better health diabetes program (community-based or online, also known as the diabetes self-management program) improves the hba1c of people with type-ii diabetes. the investigators will also examine 1) symptoms (fatigue, sleep, low blood sugar symptoms, depression, shortness of breath), 2) healthy behaviors (blood sugar monitoring; taking medications as prescribed; getting eye, foot, kidney and cholesterol exams; and activity), 3) the use of health care services. this project is a translational study to demonstrate the effectiveness of the intervention in the context of a major insurer.

self-report questionnaires and hba1c capillary blood collection kits will be administered at baseline (prior to the intervention), six-months and twelve-months. differences between baseline and followup scores will be used to determine if participants have benefited from the intervention, using intent-to-treat methodology. subgroups and delivery method (small-group or on-line) will be compared using repeated measures and analyses of covariance.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * wellpoint insurance or medicare supplement plan participant * 18 years or older exclusion criteria: * treatment for cancer in past year * pregnant * under 18 * previously taken a stanford self-management program

Keywords: diabetes patient education self management health improvement
evaluation of a cash transfer program in low-income families in guinea-bissau

Conditions: Per Capita Food Consumption Expenditure; Childhood Growth; Childhood Cognition; Anemia; School Registration and Attendence; Diabetes

Summary: this pilot study will test the effect of a cash transfer program aiming to improve family food consumption patterns, family health and schooling, with resulting benefits for childhood growth and cognition.

cash transfer (ct) programs in low-income countries that allow recipients to receive cash designated for specific household expenditures such as food and family health and education typically show significant program benefits. in particular, several programs have shown positive impacts on use of health care resources, nutrition status and self-reported health, along with significant improvements in the motor and cognitive development of young children. guinea-bissau is currently the 11th poorest country and is thus an appropriate target for a cash transfer program. this project will pilot test the effect of a 2 year cash transfer program aiming to improve family food consumption patterns, family health and schooling, with resulting benefits for childhood growth and cognition. family-wide assessment will be conducted to examine the impact in all family members. baseline and 3 follow up assessments will be completed.

Eligibility criteria:
inclusion criteria: * families (defined as groups of individuals who routinely eat together) in 3 regions of guinea-bissau. * identified by developing scale based upon household characteristics and assets per capita. as well as access to services such as water, electricity and sanitation. * families having the lowest score identified as lowest income were recruited. exclusion criteria: * families with high scores on asset scale. * families uninterested in participating.
anti-cxcr4 (bms-936564) alone and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-cxcr4 (bms-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (mtd) of bms-936564 in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone in subjects with relapsed or refractory multiple myeloma.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * subjects must have confirmed diagnosis of multiple myeloma with measurable disease excluded are subjects with only plasmacytomas, plasma cell leukemia, or non-secretory myeloma. * disease must be assessed within 28 days prior to treatment initiation. * subjects must have evidence of relapsed or relapsed/refractory disease. * subjects must have received at least 2 prior regimens for multiple myeloma. * eastern cooperative oncology group (ecog) performance status 0 - 2. * subjects must have received last treatment (ie, chemotherapy, radiotherapy, biological, immunotherapy or investigational agent \[therapeutic or diagnostic\]) at least 14 days prior to treatment initiation. the last treatment of systemically absorbed steroids must be at least 2 weeks or 5 half lives (whichever is shorter) before the first dose of bms-936564. exclusion criteria: * a serious uncontrolled medical disorder or active infection. * current or recent (within 3 months) gastrointestinal disease or condition that could impact the absorption of orally-administered drug. * inability to swallow oral medication. * uncontrolled or significant heart disease. * any other malignancy, excluding basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer stage 0, from which the subject has not been disease-free for at least 3 years.

Keywords: relapsed refractory
efficacy and safety of aliskiren administered in combination with amlodipine versus amlodipine alone in african american patients with stage 2 hypertension

Conditions: Hypertension

Summary: the purpose of the study is to evaluate the bp-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in african american patients with stage ii hypertension.


Eligibility criteria:
inclusion criteria: * men or women of african american background; self identified * patients with stage 2 hypertension defined as mssbp ≥ 160 mmhg and \< 200 mmhg at visit 5 (randomization exclusion criteria: * office blood pressure measured by cuff (msdbp ≥ 110 mmhg and/or mssbp ≥ 200 mmhg) * patients on 4 or more antihypertensive medications. * patients with uncontrolled hypertension (mssbp \>180 mmhg) taking more than 1 antihypertensive medication at visit 1 * refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmhg). therapy with a fixed dose combination of two active substances represent two drugs. * history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. * evidence of a secondary form of hypertension, including but not limited to any of the following: * coarctation of the aorta * hyperaldosteronism * unilateral or bilateral renal artery stenosis * cushing's disease * polycystic kidney disease * pheochromocytoma * known keith-wagener grade iii or iv hypertensive retinopathy. * history of angioedema due to usage of an arb or ace inhibitor. * history of hypertensive encephalopathy, cerebrovascular accident, transient ischemic attack, heart failure (nyha class ii-iv), coronary bypass graft surgery (cabg), percutaneous coronary intervention (pci), unstable angina pectoris, or myocardial infarction in the last 12 months other protocol defined inclusion/exclusion criteria applied

Keywords: hypertension african americans aliskiren amlodipine systolic blood pressure diastolic blood pressure stage ii combination
seasonal allergic rhinitis in pediatric subjects

Conditions: Rhinitis, Allergic, Perennial

Summary: the purpose of this study is to determine if the investigational drug is effective and safe in children with seasonal allergic rhinitis.


Eligibility criteria:
inclusion criteria: * diagnosis of seasonal allergic rhinitis. * adequate exposure to seasonal (spring/summer) allergen prevalent to the geographic area. exclusion criteria: * have significant concomitant medical conditions. * use of corticosteroids, other allergy meds during the study. * have abnormal ecg or laboratory abnormality.

Keywords: pediatric seasonal allergic rhinitis
the effect of music therapy on comfort, pain and anxiety

Conditions: Bone Marrow Disease; Hematological Malignancy

Summary: objectives: this study was conducted to determine the effect of music therapy on the pain, anxiety, and comfort levels of patients who underwent bone marrow aspiration and biopsy. methods: this research was conducted as a randomized controlled study in the hematology polyclinic of a university hospital. music therapy will used with the intervention group throughout the procedure. during data evaluation, paired t-test, independent t-test and effect size will used. the sample group was calculated based on the sample groups of other studies in the literature (çelebi et al., 2020; özdemir et al., 2019). according to the preliminary power analysis results using the g.power 3.1.9 program, the sample size was calculated at 80% power, at medium effect size at 5% alpha value. according to the analysis results, the sample size per group was calculated as 30. however, since there was 10% probability that some patients may drop, the sample size for the study was recalculated as 66 (experimental group: 33, control group: 33).the patients will informed about using music. in addition, it will explained that they could adjust the sound levels and that they should report when they are disturbed by the tone. music continued throughout the process. communication with the patient will maintained, and symptoms such as discomfort, anxiety were observed throughout the procedure. the music player will switched off after the procedure was completed. the patients will asked whether they had any discomfort while the music played. tthe music therapy will last an average of 30 minutes. after completing the procedures, the patient's pain, comfort, and anxiety levels were re-evaluated using vas and stai.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hematological malignancy (defined as multiple myeloma, chronic lymphocytic leukaemia, myelodysplastic syndrome or indolent lymphoma) * 18 years of age or older, * must be able to speak turkish exclusion criteria: * hearing impairment * hormonal dysfunction (adrenal, pituitary, thyroid, etc.) * sever anxiety disorder * parkinson's disease * alzheimer's disease * dementia * major depression

Keywords: bone marrow aspiration biopsy musictherapy anxiety pain comfort
explore active surveillance mode of the community's adverse event following immunization(aefi)

Conditions: Adverse Reaction to Drug

Summary: the investigators would remind the guardians of observation after immunization via sending short message and collect the information of aefi by two ways, short message/telephone and website questionnaire.

the investigators will compare the rate between active and inactive surveillance of aefi

Eligibility criteria:
inclusion criteria: * according with the regular vaccination * immunization the acellular pertussis diphtheria tetanus vaccine and measles and rubella combined vaccine exclusion criteria: * disapproval the aefi information
a intra-patient comparison of closed loop and plate haptic toric intraocular lenses

Conditions: Cataract

Summary: during cataract surgery an artificial lens is implanted in the eye. these artificial lenses are called intraocular lenses (iols) and there are many different types of iol designs. your eyes have astigmatism, which is a normal and common characteristic of the eye. if left uncorrected the astigmatism would mean that you would need to wear spectacles for viewing distance objects. new iol designs called toric iols help to correct the astigmatism to improve your vision after cataract surgery. this study has been designed to look at how well a toric iol corrects this astigmatism so that you do not need to wear spectacles for viewing distance objects. there are many designs of these toric iols and for this study we are looking to compare two different designs of toric iols by putting one lens in your right eye and a different type of lens in your left eye. both lenses are commercially available and are commonly implanted iols. using new non-invasive methods we hope to be able to better judge the visual performance of these lenses and the ability of these lenses to correct astigmatism. in addition the study will involve imaging and examining the iols to determine the prevalence of any post-operative complications.


Eligibility criteria:
inclusion criteria: * age 50-75 years, bilateral significant corneal astigmatism \>1.50d. * requiring a toric iol within the following power range: * sphere +6.00d to +30.00d * cylinder +1.00d to +6.00d exclusion criteria: * amblyopia, * predicted bilateral post-op corneal astigmatism of \<1.50d, * irregular astigmatism, * dilated pupil size smaller than 5mm, * macular pathology, * glaucoma, * retinal disease, * corneal disease, * abnormal iris, * pupil deformation and * any previous corneal or intraocular surgery.

Keywords: lenses, intraocular
prism: efficacy and safety of cobomarsen (mrg-106) in subjects with mycosis fungoides who have completed the solar study

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Summary: the main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as mrg-106) for the treatment of cutaneous t-cell lymphoma (ctcl), mycosis fungoides (mf) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the solar clinical study (mrg106-11-201). cobomarsen is designed to inhibit the activity of a molecule called mir-155 that may be important to the growth and survival of mf cancer cells. the effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. the safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.

study design: up to 60 subjects are expected to be enrolled after discontinuation from the solar clinical study (mrg106-11-201). cobomarsen will be administered in the clinic by 2-hr intravenous infusion on days 1, 3, 5 and 8, and weekly thereafter. treatment will continue until the subject becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated.

Eligibility criteria:
key inclusion criteria: * must have participated in the comparator arm of the solar clinical trial and completed the study (confirmed disease progression). key exclusion criteria: * sézary syndrome or mycosis fungoides with b2 involvement, defined as documented history of b2 and/or b2 staging at screening. * evidence of large cell transformation. * visceral involvement related to mf at screening. * unresolved toxicities from prior vorinostat treatment, defined as having not resolved to ctcae v5.0 grade 0 or 1. * any ctcl systemic therapy after completion of the solar study and prior to day 1 for prism.

Keywords: prism cutaneous t-cell lymphoma ctcl mycosis fungoides lymphoma lymphoma, t-cell lymphoma, t-cell, cutaneous lymphoma, non-hodgkin lymphoproliferative disorders lymphatic diseases immunoproliferative disorders immune system diseases neoplasms micrornas
prevention of sepsis-related organ dysfunction with allocetra-ots

Conditions: Organ Dysfunction Syndrome Sepsis

Summary: the trial evaluates the safety and efficacy of one and two doses of the study drug, allocetra-ots, in patients who have been diagnosed with sepsis.

the study drug, allocetra-ots is a cell-based therapeutic composed of donor apoptotic cells. the product contains allogeneic mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. the study drug, allocetra-ots, is based on the known activity of apoptotic cells to contribute to maintenance of peripheral immune homeostasis. as altered immune response is associated with organ dysfunction in sepsis, the possibility is being tested that the study drug can improve the condition of sepsis.

Eligibility criteria:
inclusion criteria: * suspected, presumed or documented infection from any source. * initiation of antibiotics. * meets sepsis 3 criteria: the presence of organ dysfunction as identified by a total sofa score ≥ 2 points above baseline. * adult male or female, age between 18 and 85. * gcs of \>13 with verbal score of 5. * signed written informed consent by the patient. exclusion criteria: * participation in an interventional investigational trial within 30 days prior to diagnosis of sepsis. * significant trauma requiring hospitalization within 30 days prior to diagnosis of sepsis. * surgical intervention or hospitalization within 45 days prior to diagnosis of sepsis. * pregnancy or breast-feeding female. * progressive or poorly-controlled malignancies or \< 6 month after active treatment for cancer (chemotherapy or irradiation). * terminally ill patients defined as patients that prior to the current hospitalization are expected to live \< 6 months (as assessed by the physician responsible for the patient). * known active acute or chronic viral infections, e.g. hepatitis b virus (hbv) or hepatitis c virus (hcv), human immunodeficiency virus (hiv) or other chronic infection. * known severe chronic respiratory health problems with severe pulmonary hypertension (≥40 mmhg) or respirator dependency. * known active upper gastrointestinal (gi) tract ulceration or hepatic dysfunction including but not limited to: biopsy-proven cirrhosis; portal hypertension; episodes of past upper gi bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma. * known new york heart association (nyha) class iv heart failure or unstable angina, ventricular arrhythmias, active ischemic heart disease, or myocardial infarction within six months prior to diagnosis of sepsis. * known immunocompromised state or medications known to be immunosuppressive. * organ allograft or previous history of stem cell transplantation

Keywords: allocetra-ots cell based therapy apoptotic cells